AP NEWS

Autism Disorder Treatment: Global Market Analysis 2018 - Forecast to 2025 - ResearchAndMarkets.com

December 4, 2018

DUBLIN--(BUSINESS WIRE)--Dec 4, 2018--The “Global Autism Disorder Treatment Market Analysis 2018 - Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The report contains up to date financial data derived from varied research sources to present unique and reliable analysis.Assessment of major trends with potential impact on the market during the next eight years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This research report analyzes the global markets with in-depth insights. The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level.

Annual estimations and forecasts are provided from the year 2014 to 2025 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

Key Topics Covered

1 Introduction

2 Executive Summary

3 Market Analysis

4 Porters Five Force Analysis

5 Autism Disorder Treatment Market by Type

6 Autism Disorder Treatment Market by Treatment Type

7 Autism Disorder Treatment Market by Drug

8 Geographical Segmentation

9 Vendor Landscaping

10 Company Profiles

Teva Pharmaceutical Industries Ltd.Sun Pharmaceutical Industries Ltd.Pfizer Inc.Otsuka Holdings Co. LtdNovartis AGMerck & Co. IncJohnson & Johnson Services, Inc.Eli Lilly And CompanyConsern Pharma Private LimitedBristol-Myers Squibb CompanyAllergan, PlcCoronis Partners Ltd.Curemark LLCHeptares Therapeutics LimitedIntra-Cellular Therapies Inc.

For more information about this report visit https://www.researchandmarkets.com/research/p5tbmq/autism_disorder?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181204006022/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/04/2018 03:10 PM/DISC: 12/04/2018 03:10 PM

http://www.businesswire.com/news/home/20181204006022/en

AP RADIO
Update hourly